Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back...
Zalicus (ZLCS) continues its upward trajectory from yesterday, gaining another 3% on the back yesterday's +15% run after saying it's initiated the second of two Phase 2a clinical studies with Z160, its treatment for chronic neuropathic pain.
From other sites
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagentat CNBC.com (Nov 14, 2013)
at CNBC.com (Nov 11, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs